PTC Therapeutics Files 8-K on Financials

Ticker: PTCT · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1070081

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

PTC Therapeutics dropped an 8-K on Jan 13th - check the financials!

AI Summary

On January 13, 2025, PTC Therapeutics, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, providing an update on the company's performance. Specific financial figures and operational details are expected to be elaborated within the attached exhibits.

Why It Matters

This filing provides investors with crucial updates on PTC Therapeutics' financial health and operational results, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any immediate negative news or significant changes.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The 8-K filing indicates that it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', suggesting a comprehensive financial update.

What is the significance of the 'Regulation FD Disclosure' item?

This indicates that the company is making public disclosures in compliance with Regulation Fair Disclosure, ensuring that material information is broadly disseminated.

When was PTC Therapeutics, Inc. incorporated?

PTC Therapeutics, Inc. was incorporated in Delaware.

What is the IRS Employer Identification Number for PTC Therapeutics, Inc.?

The IRS Employer Identification Number for PTC Therapeutics, Inc. is 04-3416587.

What is the primary business of PTC Therapeutics, Inc.?

PTC Therapeutics, Inc. operates in the 'Pharmaceutical Preparations' industry, with SIC code 2834.

Filing Stats: 1,221 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2025-01-13 14:00:25

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 13, 2025, PTC Therapeutics, Inc. (the "Company") issued a press release (the "press release") announcing certain preliminary (unaudited) financial information for its fiscal year ending December 31, 2024, including that the Company expects to report (i) total unaudited net revenue of approximately $814 million, (ii) total unaudited net product revenue of approximately $601 million, (iii) unaudited net product revenue for Translarna (ataluren) of approximately $340 million and unaudited net product revenue for Emflaza (deflazacort) of approximately $207 million and (iv) royalty revenue associated with Evrysdi of approximately $211 million. Final results are subject to completion of the Company's year-end audit.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 13, 2025, the Company also announced financial guidance for its fiscal year ending December 31, 2025 in the press release, including that the Company anticipates (i) full year total revenues to be between $600 million and $800 million, i ncluding in-line products, potential new product launches and royalty revenue from Evrysdi , and (ii) GAAP R&D and SG&A expense for the full year 2025 to be between $805 million and $835 million with non-GAAP R&D and SG&A expense for the full year 2025 to be between $730 million and $760 million, excluding estimated non-cash, stock-based compensation expense of $75 million. The Company announced that on Monday, January 13, 2025 at 2:15 p.m. EST at the 43rd Annual J.P. Morgan Healthcare Conference (the "Conference"), the Company will provide an update on 2024 accomplishments and highlight upcoming 2024 potential value-creating milestones. The Company will also present its preliminary 2024 unaudited financial results and 2025 financial guidance. The presentation will be webcast live on the Events and Presentations page under the Investors section of the Company's website. Following the completion of the Conference, the Company will enter an investor quiet period until it provides its next corporate update. A copy of the press release and the slide presentation are attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2 and are incorporated by reference into this Item 7.01. This Current Report on Form 8-K and Exhibits 99.1 and 99.2 include a forward-looking financial measure that was not prepared in accordance with accounting principles generally accepted in the United States (GAAP), non-GAAP R&D and SG&A expenses (which excludes non-cash stock-based compensation expense). Management uses this measure when assessing and identifying operational trends and, in management's opinion, this non-GAAP measure is useful to investors and other users of its financial statements by

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 13, 2025 issued by PTC Therapeutics, Inc. 99.2 Corporate Presentation – 43rd Annual J.P. Morgan Healthcare Conference 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PTC Therapeutics, Inc. Date: January 13, 2025 By: /s/ Pierre Gravier Name: Pierre Gravier Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing